Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Tacrolimus C:D-forhold målt i nyretransplantationsmodtagere behandlet med en gang dagligt depotpræparater (TaC:Drop)

3. november 2026 opdateret af: Edward Geissler

Multicenter, Open-label, Randomiseret, To-arm, Parallel-gruppe, Superioritetsundersøgelse for at vurdere biotilgængelighed og praktisk anvendelighed af to Tacrolimus-formuleringer én gang dagligt, Envarsus® sammenlignet med Advagraf™, administreret til nyretransplanterede modtagere

The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Detaljeret beskrivelse

This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability.

The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time.

Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters.

Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

322

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Aachen, Tyskland, 52074
        • University Hospital Aachen, Department of General, Visceral and Transplant Surgery
      • Berlin, Tyskland, 10117
        • Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
      • Bochum, Tyskland, 44892
        • Knappschaft Clinic, University Hospital Bochum, Department of Surgery
      • Dresden, Tyskland, 01307
        • University Hospital Dresden, Division of Nephrology
      • Hamburg, Tyskland, 20251
        • University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
      • Hanover, Tyskland, 30625
        • Hannover Medical School, Department of General, Visceral and Transplant Surgery
      • Jena, Tyskland, 07747
        • University Hospital Jena, Internal Medicine III, Nephrology
      • Mainz, Tyskland, 55131
        • University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
      • Mannheim, Tyskland, 68167
        • University Hospital Mannheim, Medical Clinic V
      • Munich, Tyskland, 81377
        • LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
      • Münster, Tyskland, 48149
        • University Hospital Münster, Medical Clinic D
      • Regensburg, Tyskland, 93053
        • University Hospital Regensburg, Department of Nephrology
      • Würzburg, Tyskland, 97080
        • University Hospital Würzburg, Medical Clinic I, Department of Nephrology

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Signed and dated written informed consent
  2. Adult (≥18 years old) male or female
  3. Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor
  4. ABO blood type compatible with the donor kidney
  5. Able to swallow an oral formulation of tacrolimus in tablet or capsule form

Exclusion Criteria:

  1. Multi-organ transplantation
  2. Any previous solid organ transplantation (other than a first kidney allograft)
  3. For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease
  4. Patient and/or donor is positive for active HCV, HBV or HIV infection
  5. History of any malignancy that could not be curatively treated
  6. Ongoing abuse of drugs or alcohol
  7. Signs of advanced liver disease or any signs of liver decompensation
  8. Ongoing uncontrolled systemic infection
  9. Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
  10. Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™
  11. Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides
  12. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  13. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception
  14. Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period
  15. Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
  16. Inability to freely give informed consent (e.g. individuals under legal guardianship)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Envarsus

Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

Andre navne:
  • Envarsus
Aktiv komparator: Advagraf

Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

Andre navne:
  • Advagraf

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)
Tidsramme: 12 weeks after kidney transplantation

To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory.

12 weeks after kidney transplantation

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Andel af patienter med dalniveauer lavere, inden for eller højere end målområdet
Tidsramme: 4 dage, 14 dage, 28 dage og 12 uger efter nyretransplantation
4 dage, 14 dage, 28 dage og 12 uger efter nyretransplantation
Gennemsnitligt bundniveau for tacrolimus og variabilitet mellem patienter (interval) af bundniveauer for tacrolimus
Tidsramme: 4 dage, 14 dage, 28 dage og 12 uger efter nyretransplantation
4 dage, 14 dage, 28 dage og 12 uger efter nyretransplantation
Gennemsnitlig daglig dosis af tacrolimus og variation mellem patienter (interval) af daglig dosis af tacrolimus
Tidsramme: 4 dage, 14 dage, 28 dage og 12 uger efter nyretransplantation
4 dage, 14 dage, 28 dage og 12 uger efter nyretransplantation
Variabilitet inden for patienten af ​​C/D-forhold og daglig dosis
Tidsramme: Målt over tidspunkterne: dag 4, dag 14, dag 28 og uge 12
Målt over tidspunkterne: dag 4, dag 14, dag 28 og uge 12
Incidensrate af for-årsag biopsier
Tidsramme: 12 uger efter nyretransplantation
12 uger efter nyretransplantation
Hyppigheden af ​​akutte afstødningsepisoder, der kræver behandling
Tidsramme: 12 uger efter nyretransplantation
12 uger efter nyretransplantation
Hyppigheden af ​​steroid-resistente episoder af biopsi-bevist akut afstødning
Tidsramme: 12 uger og 1 år efter nyretransplantation
12 uger og 1 år efter nyretransplantation
Forekomst af CMV- og BKV-infektion (herunder organmanifestation, hvis relevant)
Tidsramme: 12 uger og 1 år efter nyretransplantation
12 uger og 1 år efter nyretransplantation
Forekomst, type, sværhedsgrad og alvor af bivirkninger (AR'er)
Tidsramme: 12 uger og 3 år efter nyretransplantation
12 uger og 3 år efter nyretransplantation
Blodtryk
Tidsramme: 12 uger og 1, 2, 3 år efter nyretransplantation
12 uger og 1, 2, 3 år efter nyretransplantation
Forekomst af gastrointestinale lidelser, der kræver diagnostisk undersøgelse
Tidsramme: 12 uger og 3 år efter nyretransplantation
12 uger og 3 år efter nyretransplantation
Gentagelse af primær nyresygdom
Tidsramme: 12 uger og 3 år efter nyretransplantation
12 uger og 3 år efter nyretransplantation
Forekomst af de novo DSA
Tidsramme: Opdages inden for det første år efter nyretransplantation
Opdages inden for det første år efter nyretransplantation
Doser og varighed af glukokortikosteroidbehandling
Tidsramme: 12 uger og 1, 2, 3 år efter nyretransplantation
12 uger og 1, 2, 3 år efter nyretransplantation
Hyppighed og tid til at studere behandlingsophør
Tidsramme: 3 år efter nyretransplantation
3 år efter nyretransplantation
Hyppighed, tid til og årsag til patientens tilbagetrækning fra undersøgelsen
Tidsramme: 3 år efter nyretransplantation
3 år efter nyretransplantation
Time to reach the first trough level in target range
Tidsramme: Time period measured in days, assessed within the first 2 weeks after kidney transplantation

Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading

Time period measured in days, assessed within the first 2 weeks after kidney transplantation
Tacrolimus concentration/dose (C/D) ratio
Tidsramme: 4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation

The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site.

4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
Treatment failure rate
Tidsramme: 12 weeks and 1, 2, 3 years after kidney transplantation

A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause)

12 weeks and 1, 2, 3 years after kidney transplantation
Time to treatment failure after transplantation
Tidsramme: Measured until 3 years after kidney transplantation

Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause)

Measured until 3 years after kidney transplantation
Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection
Tidsramme: 12 weeks and 1, 2, 3 years after kidney transplantation

Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition.

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of graft failure
Tidsramme: 12 weeks and 1, 2, 3 years after kidney transplantation

Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation

12 weeks and 1, 2, 3 years after kidney transplantation
Mortality rate
Tidsramme: 12 weeks and 1, 2, 3 years after kidney transplantation

Mortality rate measures death from any cause

12 weeks and 1, 2, 3 years after kidney transplantation
Graft function measured by eGFR (estimated glomerular filtration rate)
Tidsramme: 4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation

eGFR calculated according to the CKD-EPI formula

4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of delayed graft function
Tidsramme: Measurable within the first 2 weeks after kidney transplantation

Delayed graft function is defined as the need for more than one episode of dialysis after transplantation

Measurable within the first 2 weeks after kidney transplantation
Incidence rate of primary non-function of the renal allograft
Tidsramme: Measurable within the first 12 weeks after kidney transplantation

Primary non-function is defined as the necessity for ongoing chronic dialysis

Measurable within the first 12 weeks after kidney transplantation
Incidence of hepatotoxicity
Tidsramme: 12 weeks and 1, 2, 3 years after kidney transplantation

Hepatotoxicity is defined as GPT or GOT levels ≥ 2.5 x upper limit of normal range

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence of de novo tremor
Tidsramme: 12 weeks and 3 years after kidney transplantation

Incidence and severity of tremor based on medical assessment by the investigator

12 weeks and 3 years after kidney transplantation
Incidence of new onset diabetes mellitus after transplantation (NODAT)
Tidsramme: 12 weeks and 1, 2, 3 years after kidney transplantation

NODAT is defined as HbA1c ≥ 6.5% or 47.5 mmol/mol or fasting plasma glucose ≥ 126 mg/dl on two separate occasions

12 weeks and 1, 2, 3 years after kidney transplantation
Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34)
Tidsramme: 12 weeks and 3 years after kidney transplantation

The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients.

12 weeks and 3 years after kidney transplantation
Dose of mycophenolate
Tidsramme: 12 weeks and 1, 2, 3 years after kidney transplantation

Including both mycophenolate mofetil and mycophenolic acid

12 weeks and 1, 2, 3 years after kidney transplantation

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Bernhard Banas, MD, University Hospital Regensburg

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. marts 2024

Primær færdiggørelse (Faktiske)

4. februar 2026

Studieafslutning (Anslået)

1. november 2028

Datoer for studieregistrering

Først indsendt

12. februar 2024

Først indsendt, der opfyldte QC-kriterier

12. februar 2024

Først opslået (Faktiske)

20. februar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • TaC:Drop
  • 2023-503531-18-00 (Anden identifikator: EUCT Number)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner